This trial is evaluating whether Epacadostat will improve 2 primary outcomes and 17 secondary outcomes in patients with Cancer of Pancreas. Measurement will happen over the course of 1 year.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Epacadostat is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"There is some evidence that cancer of pancreas can be treated with surgery; some that it can be treated with chemotherapy; some that it can be treated with surgery + chemotherapy; and some that it is impossible to diagnose." - Anonymous Online Contributor
"Pancreas cancer occurs more commonly in male than female individuals. It has been suggested that a combination of various environmental, genetic and physiological factors may be involved in triggering cancer. A strong association between pancreatic cancer and smoking is observed, and several candidate genes have been identified." - Anonymous Online Contributor
"With curative intent, a tumor with malignant potential will almost never be totally eradicated, even if the tumor is removed by curettage and/or surgery. However, with early diagnosis and treatment of pancreatic cancer-related complications, survival can be excellent and is comparable to patients who are diagnosed later during the disease course." - Anonymous Online Contributor
"Cancer of pancreas has a very high mortality as compared with general cancer rates. One of the reasons for such a high mortality is the frequent association of it with cancer of other organs. More than two thirds of pancreatic cancer cases are associated with a primary cancer (e.g., colorectal, prostate, stomach cancer). In the United States of America, there are around 4050 cases of pancreas diagnosed with cancer in every 100,000 annually. At the end of the 20th century, there were an estimated 2480 to 2804 new cases of pancreatic cancer in every 100 000 population of people each year. Over the last 100 years, the rate of incidence for the United States increased around 20-fold." - Anonymous Online Contributor
"Symptoms of pancreatic cancer such as weight loss, abdominal pain and jaundice may be early abnormalities that could be caused by both adenocarcinoma of pancreas and neuroendocrine tumour." - Anonymous Online Contributor
"About 434,800 people i the United States die from pancreas cancer each year. Which means that about one life of every nine in the United States is taken by someone i a year.\n" - Anonymous Online Contributor
"In this small analysis, higher doses of epacadostat led to modest improvements in quality of life for patients with cancer of pancreas. This could have implications for combination therapy with epacadostat. Further studies are required to determine any meaningful benefit for patients with these advanced cancers." - Anonymous Online Contributor
"Cancer of pancreas is a very common disease and is difficult to diagnose early. The use of targeted therapies in combination with immunotherapy has been proven in the metastasis of pancreatic adenocarcinoma and in pancreatic ductal adenocarcinoma, but its effectiveness in adjuvant metastatic [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) merits a further investigation." - Anonymous Online Contributor
"Although the number of respondents was small, and the number of respondents from the US and Japan was lower than that from Australia and Scandinavia, this study suggests that clinicians should play a pivotal role in making decisions regarding clinical trials for cancer of the pancreas." - Anonymous Online Contributor
"Cancer of pancreas runs in families. The fact that there were three affected siblings in the families indicates a possible genetic contribution to the disease. Future studies using linkage analysis to identify genetic risk factors for cancer of pancreas are warranted in order to help in the development of early diagnosis and better management." - Anonymous Online Contributor
"[A large number of agents were found to display antineoplastic properties against different types of cancers. (...) The use of many new antineoplastic substances with a different pharmacokinetic properties was recommended for future study, as well as clinical trials in order to determine its antineoplastic efficacy in specific tumor types or tumors, or whether it has a general effect on the survival time of patients. (...) A number of more potent agents are being used for the treatment of pancreatic cancer, such as fluoropyrimidines, etoposide, etoposide/5-fluorouracil, and gemcitabine. (..." - Anonymous Online Contributor
"The treatment was well tolerated. No significant difference was seen in progression-free survival between this study and the prior phase III study, underscoring the need for further exploration of the EZB4 targeting drug program in patients with EZH2(+) MDS." - Anonymous Online Contributor